Literature DB >> 23212614

Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines.

Yousef Najajreh1, Hazem Khamaisie, Nili Ruimi, Soliman Khatib, Joshua Katzhendler, Martin Ruthardt, Jamal Mahajna.   

Abstract

Chronic myeloid leukemia (CML) is characterized by the presence of p210(Bcr-Abl) which exhibits an abnormal kinase activity. Selective Abl kinase inhibitors have been successfully established for the treatment of CML. Despite high rates of clinical response, CML patients can develop resistance against these kinase inhibitors mainly due to point mutations within the Abl protein kinase domain. Previously, we have identified oleic acid as the active component in the mushroom Daedalea gibbosa that inhibited the kinase activity of Bcr-Abl. Here, we report that the oleyl amine derivatives, S-1-(1-Hydroxymethyl-2-methyl-propyl)-3-octadec-9-enyl-urea [oleylaminocarbonyl-L-N-valinol,oroleylaminocarbonyl-S-2-isopropyl-N-ethanolamine,oleylamine-carbonyl-L-valinol] (cpd 6) and R-1-(1-Hydroxymethyl-2-methyl-propyl)-3-octadec-9-enyl-urea [oleylamineocarbonyl-D-N-valinol, oleylaminocarbonyl-R-2-isopropyl-N-ethanolamine, or oleylamine-carbonyl-D-valinol] (cpd 7), inhibited the activity of the native and T315I mutated Bcr-Abl. Furthermore, cpd 6 and 7 exhibited higher activity towards the oncogenic Bcr-Abl in comparison to native c-Abl in SupB15 Ph-positive ALL cell line.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212614     DOI: 10.1007/s11033-012-2282-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  22 in total

Review 1.  The biology of chronic myeloid leukemia.

Authors:  S Faderl; M Talpaz; Z Estrov; S O'Brien; R Kurzrock; H M Kantarjian
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

2.  Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity.

Authors:  Hazem Khamaisie; Sherbel Sussan; Michael Tal; Yousef Najajreh; Martin Ruthardt; Jamal Mahajna
Journal:  Anticancer Res       Date:  2011-01       Impact factor: 2.480

3.  N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor.

Authors:  Yongmun Choi; Markus A Seeliger; Shoghag B Panjarian; Hakjoong Kim; Xianming Deng; Taebo Sim; Brian Couch; Anthony J Koleske; Thomas E Smithgall; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-08-13       Impact factor: 5.157

Review 4.  Automated docking of flexible ligands: applications of AutoDock.

Authors:  D S Goodsell; G M Morris; A J Olson
Journal:  J Mol Recognit       Date:  1996 Jan-Feb       Impact factor: 2.137

5.  Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.

Authors:  Kendall D Carey; Andrew J Garton; Maria S Romero; Jennifer Kahler; Stuart Thomson; Sarajane Ross; Frances Park; John D Haley; Neil Gibson; Mark X Sliwkowski
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

6.  Regulation of platelet protein kinase C by oleic acid. Kinetic analysis of allosteric regulation and effects on autophosphorylation, phorbol ester binding, and susceptibility to inhibition.

Authors:  S el Touny; W Khan; Y Hannun
Journal:  J Biol Chem       Date:  1990-09-25       Impact factor: 5.157

7.  Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.

Authors:  Tianjun Zhou; Lois Commodore; Wei-Sheng Huang; Yihan Wang; Mathew Thomas; Jeff Keats; Qihong Xu; Victor M Rivera; William C Shakespeare; Tim Clackson; David C Dalgarno; Xiaotian Zhu
Journal:  Chem Biol Drug Des       Date:  2010-11-30       Impact factor: 2.817

8.  Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Authors:  Wei-Sheng Huang; Chester A Metcalf; Raji Sundaramoorthi; Yihan Wang; Dong Zou; R Mathew Thomas; Xiaotian Zhu; Lisi Cai; David Wen; Shuangying Liu; Jan Romero; Jiwei Qi; Ingrid Chen; Geetha Banda; Scott P Lentini; Sasmita Das; Qihong Xu; Jeff Keats; Frank Wang; Scott Wardwell; Yaoyu Ning; Joseph T Snodgrass; Marc I Broudy; Karin Russian; Tianjun Zhou; Lois Commodore; Narayana I Narasimhan; Qurish K Mohemmad; John Iuliucci; Victor M Rivera; David C Dalgarno; Tomi K Sawyer; Tim Clackson; William C Shakespeare
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

9.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Authors:  Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

10.  Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.

Authors:  Tim Beissert; Alena Hundertmark; Velina Kaburova; Lorena Travaglini; Afsar A Mian; Clara Nervi; Martin Ruthardt
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

View more
  3 in total

1.  Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.

Authors:  Yifat Koren Carmi; Hatem Mahmoud; Hazem Khamaisi; Rina Adawi; Jacob Gopas; Jamal Mahajna
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

2.  Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells.

Authors:  Ofer Regev; Noa Kidan; Meshel Nicola; Hazem Khamisie; Martin Ruthardt; Jamal Mahajna
Journal:  Arch Med Sci       Date:  2020-11-20       Impact factor: 3.318

3.  2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.

Authors:  Hazem Khamaisi; Hatem Mahmoud; Jamal Mahajna
Journal:  Molecules       Date:  2022-01-26       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.